Drug intelligence / Profile preview

MLN-977

Development stage: Discontinued
Lead developer: Millennium Pharmaceuticals
Modality: Small Molecules

Overview

MLN-977 is a small molecule compound that functions as a 5-lipoxygenase (5-LOX) inhibitor. By blocking the activity of 5-LOX, it prevents the production of leukotrienes, which are potent inflammatory mediators. This mechanism of action makes MLN-977 a potential therapeutic agent for inflammatory respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The drug was developed by PharmaEngine, with Millennium Pharmaceuticals also having been involved in the development of an oral formulation, which was later discontinued.

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)

Beyond the preview

Go deeper on MLN-977.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLN-977.

Explore the full profile